SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. is trending due to the approval of its merger with Strive Enterprises, paving the way for a Bitcoin treasury company. The community is excited about the potential for a short squeeze, with some drawing comparisons to other high-flying crypto plays. With potential access to significant capital post-merger, discussions are centered around the stock's potential valuation and ability to outperform Bitcoin itself.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to the announcement of a warrant dividend, giving shareholders the opportunity to purchase additional shares at a set price, which the community sees as a strategic move. Some believe this could trigger a short squeeze, while others are analyzing the potential impact of the warrants on share dilution and broker obligations. The discussion is further fueled by a positive earnings report, with many expressing anticipation for future price movement.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending following its earnings report, despite missing estimates, due to strong forward guidance and significant growth in cloud infrastructure revenue, particularly from multi-cloud databases. The community is focused on the company's massive backlog and potential for future growth in the AI space, leading to a debate about whether the stock's surge is justified or if it's a sign of a market bubble. Discussions also revolve around the potential impact on other tech stocks and Oracle's position in the cloud computing sector.

QMMM Holdings Ltd. engages in the provision of digital advertising services. It offers interactive design, animation, art-tech and virtual technologies used in commercial campaigns. It has worked with domestic and international banks, real estate developers, amusement parks, international sports apparel, footwear brands, luxury cosmetic products, and international brands. The company was founded by Bun Kwai on July 29, 2022 and is headquartered in Hong Kong.

QMMM Holdings Ltd. - Ordinary Shares - Class A

QMMM Holdings Ltd.

QMMM is trending due to a massive short squeeze following news of a new crypto treasury strategy, leading to extreme volatility and significant gains for some traders. Community discussions revolve around the potential for continued upward momentum versus an imminent pullback, with comparisons to other high-flying stocks in the sector. Speculation abounds regarding market manipulation and the risks associated with China-based stocks.

CaliberCos, Inc. operates as an asset management firm. It provides various support services including asset management & fund set-up services, as well as lending support, construction & development management, and real estate brokerage services. The company was founded by John Christopher Loeffler II and Jennifer Schrader in January 2009 and is headquartered in Scottsdale, AZ.

CaliberCos Inc - Ordinary Shares - Class A

CaliberCos Inc 

CWD is trending due to recent volatility, with community members discussing a potential pump and dump following the company's announcement of purchasing Chainlink tokens. Concerns about possible scams, dilution, and dark pool activity are circulating, while others hope for a short squeeze and recovery. The stock's dramatic price swings are drawing attention, with comparisons to other volatile stocks in the crypto space.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amid growing investor interest in AI and e-commerce, with discussions around its potential for high growth and comparisons to other AI companies. The community is actively debating entry points, holding strategies, and the impact of upcoming earnings, while also highlighting the company's partnerships and patented technology. Some are expressing concerns about dilution and short selling, while others are very bullish for a run to double digits.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors discuss its upcoming earnings report and the potential impact on the stock's valuation, with the community weighing positive analyst sentiment against concerns about profitability. A key point of discussion revolves around the company's position in the cybersecurity sector relative to competitors and potential for long-term growth. Some traders are also focused on short-term strategies, anticipating volatility around the earnings release.

Synopsys, Inc. engages in the provision of electronic design automation (EDA) software that engineers use to design and test integrated circuits (ICs). It also offers semiconductor intellectual property (IP) products. It operates through the following segments: Design Automation, Design IP, and Software Integrity. The Design Automation segment includes silicon design, verification products and services, system integration products and services, digital, custom, and FPGA IC design software, verification software and hardware products, and manufacturing software products. The Software Integrity segment includes a solution for building security and compliance testing into the customers' software development lifecycle and supply chain. The company was founded by Aart J. de Geus, Bill Krieger, Dave Gregory, and Rick Rudell in December 1986 and is headquartered in Sunnyvale, CA.

Synopsys, Inc.

Synopsys is trending due to mixed reactions to its recent earnings report and future outlook, with investors focused on the company's exposure to macro uncertainties and the potential impact of its pending acquisition of Ansys. While some community members express confidence in the company's long-term prospects and AI-driven growth, others are concerned about the conservative guidance and its effect on the stock's valuation.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work segments. The UnCrewed System segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics shares slipped in after-hours trading&nbsp;on&nbsp;Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis (EoE).The stock closed down 1.9% at $24.02 on Tuesday and slid another 14.2% to $20.62 in after-hours trading following its Phase 2 EoE update.The decision to pull the plug on the&nbsp;EoE candidate came after&nbsp;the Phase 2 trial hit its primary goal by reducing mast cells in the esophagus, but the depletion failed to bring meaningful improvements for patients.No differences were observed between barzolvolimab and placebo in dysphagia symptom scores, endoscopic assessment of inflammation and fibrosis, or histological reduction in eosinophil infiltration.&nbsp;Celldex said the results provide direct evidence that mast cells are not a primary driver of the disease.The study confirmed barzolvolimab’s favorable safety and tolerability profile at the dosing regimen that was tested, consistent with prior studies where dosing was less frequent.&nbsp;“While we are disappointed in the clinical outcome in EoE, we are proud of our role in advancing the science for patients who need more effective treatment options,” said Chief Executive Officer Anthony Marucci.Marucci added that Celldex remains committed to barzolvolimab’s broader pipeline, with enrollment ongoing in four studies: two Phase 3 trials in chronic spontaneous urticaria and two Phase 2 trials in atopic dermatitis and prurigo nodularis.&nbsp;The company is also finalizing plans to initiate a Phase 3 program in inducible urticaria, covering cold urticaria and symptomatic dermographism.On Stocktwits, retail sentiment for Celldex was ‘bullish’ amid ‘high’ message volume.One user focused on Celldex’s pivot toward chronic spontaneous urticaria (CSU), saying investors are primarily betting on the Phase 3 program after strong Phase 2 data, which they described as better than the current standard of care.&nbsp;They noted that CSU represents a much larger commercial opportunity, with market leader Xolair bringing in more than $4 billion in revenue in 2024.<stembedurl>https://stocktwits.com/TheGunnerAB/message/625855252</stembedurl>Another user suggested the pullback could be a buying opportunity, calling it a good time to add to positions in Celldex.<stembedurl>https://stocktwits.com/StockHunter75/message/625842884</stembedurl><a href="https://stocktwits.com/symbol/CLDX">Celldex’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Celldex Therapeutics (CLDX) shares slipped in after-hours trading on Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis. (Photo credit: Getty Images)

Why Are Celldex Shares Tumbling After Hours?

The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 

Equity

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail investor chatter around Celldex Therapeutics spiked on Sunday following new Phase 2 data showing barzolvolimab provided “profound long-term” relief from angioedema in patients with chronic spontaneous urticaria (CSU).Celldex shares closed 4.5% higher at $21.26 on Friday.The company presented updated 52-week results at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Congress in Glasgow, showing that 77% of patients on barzolvolimab were angioedema-free at Week 52.&nbsp;The antibody therapy also showed up to 87% of patients reported “clinically meaningful” improvements in angioedema activity scores (AAS7).Barzolvolimab targets KIT, a receptor tyrosine kinase involved in mast cell regulation.&nbsp;In CSU, mast cells drive persistent inflammation and swelling even after standard antihistamine therapy fails.Patients with severe CSU and angioedema frequently endure disfigurement and debilitating pain, said Diane C. Young, MD, Chief Medical Officer at Celldex.&nbsp;Additional data showed an 86% mean reduction in angioedema activity in the 150 mg group and 82% in the 300 mg every-8-weeks group.&nbsp;Patients remained angioedema-free for 72% of the year-long treatment period.Retail sentiment on platforms such as Stocktwits and Reddit turned sharply bullish over the weekend, with several users highlighting the durability of symptom control and potential differentiation from existing CSU treatments like Novartis’ Xolair.The 208-patient Phase 2 trial had previously met all primary and secondary endpoints at 12 weeks.&nbsp;A global Phase 3 program is underway, targeting antihistamine-refractory CSU patients, including those previously treated with biologics.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.Celldex stock has declined 17.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded

Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock

Latest Ratings for CLDX
 DateFirmActionFromTo Sep 2021JefferiesInitiates Coverage OnBuy Sep 2021HC Wainwright & Co.MaintainsBuy Sep 2021SVB LeerinkInitiates Coverage OnOutperform
 View More...

Analyst Expectations For Celldex Therapeutics's Future

A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics

7 Analysts Have This To Say About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDX Celldex Therapeutics Inc.